

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

RE-DESIGNATION OF DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Shanghai Junshi Biosciences Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Li Xin (“**Dr. Li**”) has been re-designated from a non-executive Director to an executive Director of the Company with effect from 28 February 2024 (the “**Re-designation**”).

The biography of Dr. Li is as follows:

Dr. Li Xin (李鑫), aged 44, was appointed as a non-executive Director on 20 October 2023 and has been serving as the Senior Vice President of Government Affairs of the Company since 28 February 2024. From September 2014 to December 2020, she served as the vice president of Greenland Financial Holdings Group Co., Ltd.*. She has been serving as the vice president of Greenland Jinchuang Technology Group Co., Ltd.* (綠地金創科技集團有限公司) since January 2021; a director of Greenland Digital Technology Co., Ltd.* (綠地數字科技有限公司) since August 2022; and an executive director of Shanghai Jiakai Investment Management Co., Ltd.* since April 2015.

She obtained a Ph.D degree in Enterprise Development and Strategic Management from Fudan University in 2005 and obtained an Executive Master of Business Administration (EMBA) degree from the Tsinghua University PBC School of Finance.

The Company has entered into a service contract with Dr. Li in relation to her appointment as a non-executive Director for a term commencing from 20 October 2023 and expiring on the conclusion of the term of the third session of the Board. The term of office is determinable by either party serving on the other not less than three months’ written notice, and subject to retirement by rotation and re-appointment in accordance with the articles of association of the Company and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”). Other than that, she has not entered into nor proposed to enter into any service contracts, which fall within the meaning of Rule 13.68 of the Listing Rules requiring the prior approval of shareholders of the Company (the “**Shareholders**”) at general meetings, with the Company. The remuneration of Dr. Li will be determined with reference to her duties and responsibilities in the Company and prevailing market conditions, and will be subject to review by the Board and the Remuneration and Appraisal Committee of the Company from time to time.

As at the date of this announcement, Dr. Li is interested in 12,060 A shares of the Company (“**Shares**”) and 82,854 H Shares, representing approximately 0.0016% of the total number of issued A Shares and approximately 0.0378% of the total number of issued H Shares, respectively. 41,654 H Shares out of the 82,854 H Shares were indirectly held by Dr. Li through an investment fund, while the 12,060 A Shares and the remaining 41,200 H Shares were directly held by Dr. Li.

As at the date of this announcement, save as disclosed above, Dr. Li has confirmed that she: (i) does not hold any position in the Company or any other subsidiaries of the Company, nor did she hold any directorship or positions of supervisor in any other listed companies in Hong Kong or overseas in the last three years; (ii) does not have any relationship with any directors, supervisors, senior management or substantial shareholders (as defined in the Listing Rules) of the Company; and (iii) does not have any interests in the shares or underlying shares of the Company or any of its associated corporations within the meaning of Part XV of the SFO.

Save as disclosed above, there are no other matters concerning the Re-designation that need to be brought to the attention of the Shareholders nor any information required to be disclosed pursuant to the requirements of Rule 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to welcome Dr. Li taking up the new role.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 28 February 2024

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Mr. Zhang Zhuobing, Dr. Yao Sheng, Mr. Li Cong, Dr. Zou Jianjun, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Feng Hui and Mr. Tang Yi as non-executive Directors; and Dr. Roy Steven Herbst, Mr. Qian Zhi, Mr. Zhang Chun, Dr. Feng Xiaoyuan and Dr. Meng Anming as independent non-executive Directors.

* *For identification purpose only*